BRAF and melanoma: Adjuvant therapy, including immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) or cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) proteins, and targeted therapy with BRAF plus MEK inhibitors, has improved the clinical prognosis for postoperative melanoma patients at high risk of recurrence.